References relevant to drug promotion: 1990-1999
This page lists all the 2058 references relevant to drug promotion in the Healthy Skepticism library that were published in 1990-1999 .
Click on the HSL (Health Skepticism Library) number for more details which may include an abstract or full text.
HSL2464
Isaacs D, Fitzgerald D.
Seven alternatives to evidence based medicine.
BMJ 1999 Dec 18-25;319(7225):1618
http://bmj.bmjjournals.com/cgi/content/full/319/7225/1618
HSL8580
Business outlook 2000: here we come!
Drug Topics 1999 Dec 6;143:76-78, 80, 82, 87-88, 90, 93-9
HSL8537
Marshall G.
Common market
Chemist and Druggist 1999 Dec 4;252
HSL7466
Lovdahl U, Riska A, Riska E.
Gender display in Scandinavian and American advertising for antidepressants.
Scand J Public Health 1999 Dec;27(4):306-10
HSL7517
Lexchin J.
Re: the promotion of Rocmaline (arginine, malic acid) in French-speaking Africa
1999 Dec
HSL8524
Anon .
R&D success boosts brand name pharmaceuticals
HealthCare Distributors 1999 Dec;51:12-14, 16, 18-20
HSL8561
Hollenbeak CS.
The effect of generic competition on prescription to over-the-counter switching.
Pharmacoeconomics 1999 Dec;16(6):661-8
HSL8742
Jensen MJ.
Development of a searchable Internet database to provide medical information from a pharmaceutical company to health care professionals
ASHP Midyear Clinical Meeting 1999 Dec;34
HSL8744
Mehl B.
Pharmaceutical trends: overview of factors responsible for increasing pharmaceutical expenditures
ASHP Midyear Clinical Meeting 1999 Dec;34
HSL8745
Stein GC.
Current federal regulatory trends
ASHP Midyear Clinical Meeting 1999 Dec;34
HSL12717
Daughton CG, Ternes TA.
Pharmaceuticals and personal care products in the environment: agents of subtle change?
Environ Health Perspect 1999 Dec;107
Link to source with long URL
HSL7516
Pirisi A.
Patient-directed drug advertising puts pressure on US doctors
Lancet 1999 Nov 27;354:1887
*news story/United Kingdom/United States/
HSL2516
Wynia MK, Latham SR, Kao AC, Berg JW, Emanuel LL.
Medical professionalism in society.
N Engl J Med 1999 Nov 18;341(21):1612-6
http://content.nejm.org/cgi/content/extract/341/21/1612
HSL7474
Price VH.
Authors' conflicts of interest: a disclosure and editors' reply.
N Engl J Med 1999 Nov 18;341(21):1618-9
HSL8560
Conlan MF.
Bill goes after Flo as battle for Medicare Rx benefit heats up
Drug Topics 1999 Nov 15;143:71
HSL7456
Johansen HK, Gotzsche PC.
Problems in the design and reporting of trials of antifungal agents encountered during meta-analysis.
JAMA 1999 Nov 10;282(18):1752-9
http://jama.ama-assn.org/cgi/content/full/282/18/1752
HSL7515
Rennie D.
Fair conduct and fair reporting of clinical trials.
JAMA 1999 Nov 10;282(18):1766-8
http://jama.ama-assn.org/cgi/content/full/282/18/1766
HSL7514
Pakenham-Walsh N, Eddleston M, Kaur M.
Developing world needs access to low cost pharmaceutical information from reliable sources.
BMJ 1999 Nov 6;319(7219):1265
Link to source with long URL
HSL5859
Bell RA, Kravitz RL, Wilkes MS.
Direct-to-consumer prescription drug advertising and the public.
J Gen Intern Med 1999 Nov 01;14(11):651-7
http://www.blackwell-synergy.com/doi/abs/10.1046/j.1525-1497.1999.01049.x
HSL8735
With 100 days to Y2K, some health care settings remained vulnerable
American Journal of Health System Pharmacy 1999 Nov 1;56:2181
HSL2158
Jackson C, Mcguire T, Dommers E, Nyst P.
A GP prescribing educational intervention involving a medication panel.
Aust Fam Physician 1999 Nov;28(11):1191-5
HSL2159
Slawson DC, Shaughnessy AF.
Teaching information mastery: creating informed consumers of medical information.
J Am Board Fam Pract 1999 Nov-Dec;12(6):444-9
HSL7457
Kjaergard LL, Nikolova D, Gluud C.
Randomized clinical trials in hepatology: predictors of quality.
Hepatology 1999 Nov;30(5):1134-8
Link to source with long URL
HSL7510
Charlish P.
DTC advertising encourages consumers to talk about drugs
Scrip Magazine 1999 Nov:9-10
www.pjbpubs.co.uk/scrip/scrhome.html
HSL7511
Law J.
Preparing to advertising directly to the European consumer
Scrip Magazine 1999 Nov(84):6-7
www.pjbpubs.co.uk/scrip/scrhome.html
HSL7513
Redelmeier DA.
Drug dependence in a journal club.
ACP J Club 1999 Nov-Dec;131(3):A13-4
HSL8361
Allen J.
Surgical internet at a glance: healthcentral and drKoop.
Am J Surg. 1999 Nov;178(5):359
http://linkinghub.elsevier.com/retrieve/pii/S0002-9610(99)00214-7
HSL8554
Hallahan M, Madell R.
Rx branding: brand new culture
Pharmaceutical Executive 1999 Nov;19:98-100, 102, 104
HSL8555
Wechsler J.
DTC dilemma
Pharmaceutical Executive 1999 Nov;19:22, 24, 26-27
HSL8556
Pal S.
Generic industry market review
US Pharmacist 1999 Nov;19(24):9, 14-15, 22-23, 30, 34
HSL8578
Beavers N.
Generic industry abuzz over Medicare, exclusivity proposals
Drug Topics 1999 Nov;143
HSL7437
Bosch X.
Spain investigates "bribery" of doctors.
Lancet 1999 Oct 30;354(9189):1537
HSL7473
Phillips SG, Carey LA.
Whose article is it anyway?
Lancet 1999 Oct 30;354(9189):1563
HSL7434
Armstrong K, Schwartz JS, Asch DA.
Direct sale of sildenafil (Viagra) to consumers over the Internet.
N Engl J Med 1999 Oct 28;341(18):1389-92
http://content.nejm.org/cgi/content/extract/341/18/1389
HSL7448
Friedberg M, Saffran B, Stinson TJ, Nelson W, Bennett CL.
Evaluation of conflict of interest in economic analyses of new drugs used in oncology.
JAMA 1999 Oct 20;282(15):1453-7
http://jama.ama-assn.org/cgi/content/full/282/15/1453
HSL7509
Krimsky S.
Conflict of interest and cost-effectiveness analysis.
JAMA 1999 Oct 20;282(15):1474-5
http://jama.ama-assn.org/cgi/content/full/282/15/1474
HSL8734
Krimsky S.
Conflict of interest and cost-effectiveness analysis.
JAMA 1999 Oct 20;282(15):1474-5
http://jama.ama-assn.org/cgi/content/full/282/15/1474
HSL8536
van den Hoogen H, Hooijman G, Meulepas M.
Bottom up approach of local pharmacotherapeutic consultations involving pharmacists and general practitioners
Pharmaceutisch Weekblad 1999 Oct 15;134:1400-1404
HSL7507
Mansfield P.
Debate: drug advertising
Australian Doctor 1999 Oct 8:64
HSL7508
McLean DL.
Debate: drug advertising
Australian Doctor 1999 Oct 8:64
HSL7504
Alper PR.
Direct-to-consumer advertising: education or anathema?
JAMA 1999 Oct 6;282(13):1226-7
http://jama.ama-assn.org/cgi/content/full/282/13/1226
HSL7505
Holmer AF.
Direct-to-consumer advertising: Education or anathema? [reply]
JAMA 1999 Oct 6;282(13):1227-1228
HSL7506
Rosner F, Kark P, Packer S, Bennett A, Berger J.
Direct-to-consumer advertising: education or anathema?
JAMA 1999 Oct 6;282(13):1227
HSL8739
New community pharmacy foundation to benefit from lawsuits against drug companies
American Journal of Health System Pharmacy 1999 Oct 1;56:1912, 1915
HSL1221
Lexchin J.
Don't bite the hand that feeds you.
West J Med 1999 Oct;171(4):238-9
Link to source with long URL
HSL7449
Glassman PA, Hunter-Hayes J, Nakamura T.
Pharmaceutical advertising revenue and physician organizations: how much is too much?
West J Med 1999 Oct;171(4):234-8
Link to source with long URL
HSL8553
Bowles R, Howell P, Ott T, Heller S.
Medicare Rx benefits: implications for the pharmaceutical industry
Pharmaceutical Executive 1999 Oct;19:62, 64, 66, 68, 70
HSL8583
Settlement funds: distribution decided in price-fixing case
America's Pharmacist 1999 Oct;121:20-21
HSL8597
Wechsler J.
Controversy over prescription drug advertising stimulates policy changes
Formulary 1999 Oct;34:878-879
HSL8599
Schwartz RM.
TV ad campaign fights Clinton Rx plan
American Druggist 1999 Oct;216:15
HSL2381
Drug-company decision to end cancer trial.
Lancet 1999 Sep 25;354(9184):1045
http://linkinghub.elsevier.com/retrieve/pii/S0140673699003207
HSL7502
Rhame FS.
Implications of "market baskets," a pharmaceutical marketing practice.
JAMA 1999 Sep 22-29;282(12):1134
http://jama.ama-assn.org/cgi/content/full/282/12/1134
HSL7445
Elston MJ.
Following the rules in marketing.
CMAJ 1999 Sep 21;161(6):685
http://www.cma.ca/cmaj/vol-161/issue-6/letters-6.htm
HSL8737
FDA finalizes guidance on DTC broadcast ads
American Journal of Health System Pharmacy 1999 Sep 15;56:1815
HSL8738
Congress explores limits on Internet pharmacy
American Journal of Health System Pharmacy 1999 Sep 15;56:1812
HSL8564
Newton P.
Promotion vs regulation
Chemist and Druggist 1999 Sep 11:27
HSL4147
Dyer C.
Incontinence campaign tests limits of advertising rules.
BMJ 1999 Sep 4;319(7210):591
http://bmj.bmjjournals.com/cgi/content/full/319/7210/591
HSL2219
The fine line between education and marketing..
Proj Inf Perspect 1999 Sep 01(28):1-3
HSL322
Vandenbroucke JP, Helmerhorst FM, Rosendaal FR.
Competing interests and controversy about third generation oral contraceptives: BMJ readers should know whose words they read.
BMJ 1999 Sep;319(7213):795-6
http://bmj.bmjjournals.com/cgi/content/full/320/7231/381/a
HSL8359
Mani MK.
A Faustian bargain.
Natl Med J India 1999 Sep-Oct;12(5):244-5
Link to source with long URL
HSL8558
Koberstein W.
Media Mix: Rx marketers blend consumer & medical campaigns
Pharmaceutical-Executive 1999 Sep;19:46-47
HSL8559
Koberstein W.
Media Mix masters: PE's annual agency roundtable
Pharmaceutical Executive 1999 Sep;19:50-84
HSL8565
Morris L.
DTC & Rx costs: circumstantial case
Pharmaceutical Executive 1999 Sep;19:20
HSL8585
Lyftingsmo S.
Survey on labeling 1999
International Pharmacy Journal 1999 Sep-Oct;13:127
HSL8611
Colchamiro R.
Generic drugs: patent wars rage on
American Druggist 1999 Sep;216:33-34, 36-38, 40, 42
HSL7451
Hafeez A, Mirza Z.
Responses from pharmaceutical companies to doctors' requests for more drug information in Pakistan: postal survey.
BMJ 1999 Aug 28;319(7209):547
http://www.bmj.com/cgi/content/full/319/7209/547
HSL2456
Bucher HC, Guyatt GH, Cook DJ, Holbrook A, McAlister FA.
Users' guides to the medical literature: XIX .Applying clinical trial results. A. How to use an article measuring the effect of an intervention on surrogate end points. Evidence-Based Medicine Working Group.
JAMA 1999 Aug 25;282(8):771-8
http://jama.ama-assn.org/cgi/content/full/282/8/771
HSL7501
Glaser T.
Yes . . . but what solutions?
BMJ 1999 Aug 23;319(7208):525
http://bmj.com/cgi/eletters/319/7208/525/a#4335
HSL7500
Dunea G.
Fancy drugs for worried folks.
BMJ 1999 Aug 21;319(7208):525A
HSL7499
Vermeulen L.
Clarification and amplification
BMJ 1999 Aug 20;319(7208):525
http://bmj.com/cgi/eletters/319/7208/525/a#4335
HSL7479
Ruffmann R.
Funding of clinical research.
Lancet 1999 Aug 14;354(9178):602
HSL2360
Silverstein K.
Millions for Viagra, Pennies for the Poor
The Toronto Star 1999 Aug 13
HSL7498
Cottle M.
Selling shyness: how doctors and drug companies created the “social phobia” epidemic
New Republic 1999 Aug 2
HSL8741
Sellers JA.
Medicare drug benefit.
Am J Health Syst Pharm 1999 Aug 1;56(15):1503
http://www.ajhp.org/cgi/reprint/56/15/1503
HSL7446
Ferguson RP, Rhim E, Belizaire W, Egede L, Carter K, Lansdale T.
Encounters with pharmaceutical sales representatives among practicing internists.
Am J Med 1999 Aug;107(2):149-52
http://linkinghub.elsevier.com/retrieve/pii/S0002934399001928
HSL8590
Schwartz H.
Unlikely support
Pharmaceutical Executive 1999 Aug;19:26, 28
HSL8593
Smith D.
Does your DTC message pass the consumer litmus test?
Pharmaceutical-Executive 1999 Aug;19:9
HSL8727
Rankin K.
Generic manufacturers look to Washington for change
Pharmacy Times 1999 Aug;66:79-80, 82
HSL7450
Griffith D.
Reasons for not seeing drug representatives.
BMJ 1999 Jul 10;319(7202):69-70
http://www.bmj.com/cgi/content/full/319/7202/69
HSL7459
Larkin M.
Whose article is it anyway?
Lancet 1999 Jul 10;354(9173):136
HSL7497
Barents Group LLC
Factors affecting the growth of prescription drug expenditures
Washington, D.C: National Institute for Health Care Management Research and Educational Foundation; 1999 Jul 9
HSL5855
Bates DW, Teich JM, Lee J, Seger D, Kuperman GJ, Ma'Luf N, Boyle D, Leape L.
The impact of computerized physician order entry on medication error prevention.
J Am Med Inform Assoc 1999 Jul-Aug 01;6(4):313-21
http://www.jamia.org/cgi/content/full/6/4/313
HSL2436
Elstein AS.
Heuristics and biases: selected errors in clinical reasoning.
Acad Med 1999 Jul;74(7):791-4
Nil
HSL2177
Eckardt VF.
[Promoting research and graduate education by the pharmaceutical industry--scientific progress or marketing strategy?]
Z Gastroenterol. 1999 Jul;Suppl 2:19-27
HSL7439
Chepesiuk R.
Keeping pharmaceutical advertising on track.
Can Fam Physician 1999 Jul;45:1652-3
HSL8572
Neuman SL.
Year 2000 in pharmacy: business as usual or disaster in progress?
Journal of Managed Care Pharmacy 1999 Jul-Aug;5:305, 308-310
HSL8594
Wang JC.
Beyond DTC: what to do if FDA scales back DTC advertising
Pharmaceutical Executive 1999 Jul;19:58-60
HSL8603
Sesti LM.
Principles of pharmacy . . . ethics & practice. Part 2
Michigan Pharmacist 1999 Jul-Aug;37:44-45
HSL8609
Smith D.
Risk management: consumer holds the trump card
Pharmaceutical Executive 1999 Jul;19:2
HSL8610
Morris L.
Reminder and help-seeking ads: alive and well
Pharmaceutical Executive 1999 Jul;19:14
HSL8612
West D.
DTC decisions: from revolution to evolution
Pharmaceutical Executive 1999 Jul;19:4-6, 8
HSL8613
Breu J.
Will patent-holder's tactics forestall generic competition?
Drug Topics 1999 Jul;143
HSL365
Warlow C, Sandercock P, Dennis M, Wardlaw J.
Research funding.
Lancet 1999 Jun 26;353(9171):2250
Nil
HSL7458
Koepp R, Miles SH.
Meta-analysis of tacrine for Alzheimer disease: the influence of industry sponsors.
JAMA 1999 Jun 23-30;281(24):2287-8
http://jama.ama-assn.org/cgi/content/full/281/24/2287
HSL2359
Galewitz P.
Study: Drugmaker Ads Can Backfire
AP Business Writer 1999 Jun 17
HSL7463
Lexchin J.
PMAC code of marketing practices.
CMAJ 1999 Jun 1;160(11):1556
http://www.cma.ca/cmaj/vol-160/issue-11/letters-11.htm#7
HSL2410
Bell RA, Wilkes MS, Kravitz RL.
Advertisement-induced prescription drug requests: patients' anticipated reactions to a physician who refuses.
J Fam Pract 1999 Jun;48(6):446-52
HSL364
Williams AH, Rowell M.
Private enterprise and public good: ethical issues in the funding of clinical research.
Ann R Coll Physicians Surg Can 1999 Jun;32(4):227-31
Nil
HSL7496
Lexchin J.
Re: the promotion of Atrovent (ipratropium bromide)
1999 Jun
HSL8568
Smith D.
Who says consumers can't make decisions?
Pharmaceutical Executive 1999 Jun;19:19
HSL8569
Prince R.
Generic firms seek government help to fight manufacturers for drug marketing rights
Pharmacy Practice News 1999 Jun;26:1, 16
HSL8570
West D.
Crop at the top: popular ad shops of the DTC world
Pharmaceutical Executive 1999 Jun;19:6-8, 10, 12, 14
HSL8571
Wechsler J.
Risky business
Pharmaceutical Executive 1999 Jun;19:3
HSL8777
Rolland PD, Kablinger AS.
Recruitment for clinical trials: psychopharmacology research clinic's experience in recruiting for depression studies
ASHP Annual Meeting 1999 Jun;56
HSL8778
Hatwig CA, Ritz P, Nunan R, Ferer M, Dunwoody C.
Designing and implementing a public relations campaign for pharmacists
ASHP Annual Meeting 1999 Jun;56
HSL7470
Mansour P.
More lessons from unfortunate events in Toronto.
Lancet 1999 May 29;353(9167):1888
HSL8598
Bremer S.
Let the good times roll
Chemist and Druggist 1999 May 29;251:16, 18, 20
HSL7442
Donohoe MT, Matthews H.
Wasted paper in pharmaceutical samples.
N Engl J Med 1999 May 20;340(20):1600
HSL7440
Dieppe P, Chard J, Tallon D, Egger M.
Funding clinical research.
Lancet 1999 May 8;353(9164):1626
HSL5840
Chan DH, Leclair K, Kaczorowski J.
Problem-based small-group learning via the Internet among community family physicians: a randomized controlled trial.
MD Comput 1999 May-Jun 01;16(3):54-8
HSL7462
Lexchin J.
How patient outcomes are reported in drug advertisements.
Can Fam Physician 1999 May;45:1213-6
HSL7493
Dr. Celebrity
Consumer Reports 1999 May:8-9
HSL7494
Molloy DW, Smith SD, Jubelis RM.
The Ideal Detail Program - comprehensive, up-to-date drug detailing
Health Law in Canada 1999 May;19(4):89-95
HSL7495
Paytash CA.
The learned intermediary doctrine and patient package inserts: a balanced approach to preventing drug-related injury.
Stanford Law Rev 1999 May;51(5):1343-71
HSL8574
West D.
Sensitivity training
Pharmaceutical Executive 1999 May;19
HSL8587
Smith DL.
Your patient package insert: does it help or hinder?
Pharmaceutical Executive 1999 May;19
HSL8595
West D.
Remote control? DTC ponders the twilight zone of TV advertising
Pharmaceutical Executive 1999 May;19
HSL8596
Wechsler J.
Regulating the Internet
Pharmaceutical Executive 1999 May;19
HSL12275
Lee TH.
Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. What constitutes a useful economic study? The health systems perspective.
Am Heart J. 1999 May;137(5):S67-70
Link to source with long URL
HSL2727
Wang TJ, Ausiello JC, Stafford RS.
Trends in antihypertensive drug advertising, 1985-1996.
Circulation 1999 Apr 20;99(15):2055-7
http://circ.ahajournals.org/cgi/reprint/99/15/2055
HSL8736
Conlan MF.
Hot issues
Drug Topics 1999 Apr 19;143:80-82, 84, 87, 89
HSL8761
APhA sets policy on telepharmacy, DTC ads, unions
American Journal of Health System Pharmacy 1999 Apr 15;56:706-707
HSL7492
Working Group on Women and Health Protection
To do no harm: DTC advertising of prescription drugs
1999 Apr 12
www.hc-sc.gc.ca/hpb-dgps/therapeut/htmleng/consult_dtca.html
HSL2357
Schonhofer PS
Dipyrone (Metamizol): Restored to good repute?
Internistische Praxis 1999 Apr 09;39:184-185
http://www.essentialdrugs.org/edrug/archive/199904/msg00014.php
HSL4150
Health Products and Food Branch, Health Canada.
Direct-to-consumer advertising of prescription drugs. [discussion document].
: Health Products and Food Branch, Health Canada.; 1999 Apr 6
!www.hc-sc.gc.ca/hpfb-dgpsa/oria-bari/99-04-14_3_e.html.
HSL7491
Therapeutic Products Programme
Discussion document: direct-to-consumer advertising of prescription drugs
1999 Apr 6
www.hc-sc.gc.ca/hpb-dgps/therapeut/htmleng/consult_dtca.html
HSL7486
Leach B.
Marketing forces
The Health Exchange 1999 Apr:8-9
HSL7489
Pharmaceutical Manufacturers Association of Canada
Advertising of prescription medicines to Canadian consumers: PMAC’s position
Ottawa: Pharmaceutical Manufacturers Association of Canada; 1999 Apr
Link to source with long URL
HSL7490
Hayes L, Smith D.
Drug industry sponsorship: at what price?
HAI News 1999 Apr(106):1-2, 15-16
HSL8607
Nolan A.
Issues & priorities for the pharmaceutical industry in Ireland
Irish Pharmacy Journal 1999 Apr;77:112-114
HSL8733
Buckley B.
Prescriptions grow 7% to 2.4 billion; sales increase 16% to $94 billion
Pharmacy Times 1999 Apr;65:16-18, 21-22
HSL2358
Ragg M.
Capsule or pill, don't swallow it whole
Weekend Australian 1999 Mar 27
HSL7472
Nathan DG, Weatherall DJ.
Academia and industry: lessons from the unfortunate events in Toronto.
Lancet 1999 Mar 6;353(9155):771-2
http://linkinghub.elsevier.com/retrieve/pii/S0140673699000720
HSL2140
Razack S, Arbour L, Hutcheon R.
Proposed model for interaction between residents and residency training programs, and pharmaceutical industry.
Ann R Coll Physicians Surg Can 1999 Mar;32(2):93-6
HSL7487
Law J.
Who will be the new voice of patients?
Scrip Magazine 1999 Mar:30-33
www.pjbpubs.co.uk/scrip/scrhome.html
HSL7488
Memoirs of methods used to sell drugs
MaLAM International News 1999 Mar-Apr;17(3-4):1-6
HSL8601
Kravetz S.
Pharmacy profession unites to endorse collaborative drug therapy management
Pharmacy Practice News 1999 Mar;26:10, 18
HSL8602
Wilcock M.
Take the heat out of prescribing
Pharmacy in Practice 1999 Mar;9:86-87
HSL8606
Bloom MZ.
Direct-to-consumer advertising provides challenge to managed care
Journal-of-Managed-Care-Pharmacy 1999 Mar-Apr;5:101-103, 106
HSL8760
Wechsler J.
Taking steps toward harmonization with Europe and Japan
Pharmaceutical Technology 1999 Mar;23:16, 18, 20-22, 24, 26, 28, 30
HSL8776
Consumers want details about prescription drugs; many use alternative medicines
American Journal of Health System Pharmacy 1999 Feb 15;56:307
HSL367
Wahlbeck K, Adams C.
Beyond conflict of interest: Sponsored drug trials show more-favourable outcomes.
BMJ 1999 Feb 13;318(7181):465
Nil
HSL370
Shuchman M.
Independent review adds to controversy at Sick Kids.
CMAJ 1999 Feb 9;160(3):386-8
http://www.cmaj.ca/cgi/reprint/160/3/386
HSL7469
Mandelkern M.
Manufacturer support and outcome.
J Clin Psychiatry 1999 Feb;60(2):122-3
HSL7485
Advertising of antibacterials
Health Skepticism 1999 Feb;2(2):1-5
HSL8730
Troy T.
Clinical independence meets demands of government, health care users
Managed Healthcare 1999 Feb;9:30
HSL8732
Zoeller J.
Top 200 drugs: aggressive detailing and direct-to-consumer advertising are landing new products in the top 200 rankings much sooner
American Druggist 1999 Feb;216:41-44, 46, 48
HSL8750
West D.
United they stand: patient care providers and DTC campaigns shake on it
Pharmaceutical Executive 1999 Feb;2:6-8
HSL2461
Greenhalgh T.
Narrative based medicine: narrative based medicine in an evidence based world.
BMJ 1999 Jan 30;318(7179):323-5
http://bmj.bmjjournals.com/cgi/content/full/318/7179/323
HSL4143
Holmer AF.
Direct-to-consumer prescription drug advertising builds bridges between patients and physicians.
JAMA 1999 Jan 27;281(4):380-2
http://jama.ama-assn.org/cgi/content/full/281/4/380
HSL7455
Hollon MF.
Direct-to-consumer marketing of prescription drugs: creating consumer demand.
JAMA 1999 Jan 27;281(4):382-4
http://jama.ama-assn.org/cgi/content/full/281/4/382
HSL8779
Holmer AF.
Direct-to-consumer prescription drug advertising builds bridges between patients and physicians.
JAMA 1999 Jan 27;281(4):380-2
http://jama.ama-assn.org/cgi/content/full/281/4/380
HSL8788
Landis NT.
Requirements for FDA-approved patient information spelled out in final rule
American Journal of Health System Pharmacy 1999 Jan 15;56:107-108
HSL8790
Landis NT.
Community pharmacy pricing suit dismissed
American Journal of Health System Pharmacy 1999 Jan 15;56:113
HSL2355
Zuger A.
Fever Pitch: Getting Doctors To Prescribe Is Big Business
New York Times 1999 Jan 11
HSL5247
Ravindran GD.
The physician and the pharmaceutical industry: both must keep the patient's interests at heart.
Issues Med Ethics 1999 Jan-Mar;7(1):21-2
HSL7483
Advertising of CCBs for hypertension
Health Skepticism 1999 Jan;2(1):3-4
HSL7484
Lexchin J.
Re: the promotion of Zaditen (ketotifen)
1999 Jan
HSL8749
Gilderman A, Salas JC, Khoury-Chamoun L.
The effectiveness of an antibiotic use program.
Manag Care Interface 1999 Jan;12(1):73-6
HSL8755
Wechsler J.
Policy issues for 1999
Pharmaceutical Executive 1999 Jan;19:20, 22, 26
HSL8763
Wechsler J.
Prices, patients, privacy top 1999 agenda
Pharmaceutical Technology 1999 Jan;23:14, 16-18, 20, 22, 24, 27
HSL2397
Heuer RJ.
. Psychology of Intelligence Analysis : Center for the Study of Intelligence, US Central Intelligence Agency; 1999
http://www.cia.gov/csi/books/19104/index.html
HSL2220
Gaedeke RM, Tootelian DH, Sanders EE.
Value of services provided by pharmaceutical companies: perceptions of physicians and pharmaceutical sales representatives.
Health Mark Q 1999;17(1):23-31
HSL2692
Dolovich L, Levine M, Tarajos R, Duku E.
Promoting optimal antibiotic therapy for otitis media using commercially sponsored evidence-based detailing: A prospective controlled trial.
Drug Information Journal 1999;33(4):1067-1077
Link to source with long URL
HSL2709
Jones , M. , Greenfield , S. , Bradley , C
A survey of the advertising of nine new drugs in the general practice literature.
Journal of Clinical Pharmacy and Therapeutics 1999;24:451-460
http://www.blackwell-synergy.com/doi/full/10.1046/j.1365-2710.1999.00255.x
HSL7431
A farewell to sales reps
Prescrire International 1999;8(41):66
HSL7432
Sales representatives: a damning report by Prescrire reps monitoring network
Prescrire International 1999;8(41):86-89
HSL7433
Angell M, Wood AJJ.
Authors’ conflicts of interest: a disclosure and editors’ reply
New England Journal of Medicine 1999;341:1618-1619
HSL7435
Ashraf H.
MCA reconsiders drug advertising on the web
Lancet 1999;353:2136
HSL7438
Bradbury J.
Storm over WHO-ISH hypertension guidelines
Lancet 1999;353:563
HSL7441
Djulbegovic B, Bennett CL, Lyman GH.
Violation of the uncertainty principle in conduct of randomized controlled trials (RCTs) of erythropoietin (EPO)
Blood 1999;94(supplement 1):399a
HSL7443
Donovan J.
Advertising pharmaceuticals to Australian
Australian Prescriber 1999;22:74-75
http://www.australianprescriber.com/magazines/vol22no4/editorial.htm
HSL7444
Dorman PJ, Counsell C, Sandercock P.
Reports of randomized trials in acute stroke, 1955 to 1995:What proportions were commercially sponsored?
Stroke 1999;30:1995-8
http://stroke.ahajournals.org/cgi/content/full/30/10/1995
HSL7447
Ford AR
A different prescription: considerations for women’s health groups contemplating funding from the pharmaceutical industry
Toronto: National Network on Environment and Women’s Health; 1999
HSL7452
Herxheimer A.
Leaflets with NSAIDs do not warn users clearly—a UK survey
Pharmaceutical Journal 1999;262:559-561
HSL7453
Hoffman JR, Wilkes M.
Direct to consumer advertising of prescription drugs: An idea whose time should not come.
BMJ 1999;318:1301-2
http://www.bmj.com/cgi/content/full/318/7194/1301
HSL7460
Lexchin J.
Direct-to-consumer advertising: impact on patient expectations regarding disease management
Disease Management & Health Outcomes 1999;5:273-283
HSL7461
Lexchin J.
Following the rules in marketing
Canadian Medical Association Journal 1999;161:685-686
http://www.cma.ca/cmaj/vol-161/issue-6/letters-6.htm#4
HSL7464
Lexchin J.
To the editor
Journal of Emergency Medicine 1999;17:905
HSL7465
Liebeskind DS, Kidwell CS, Saver JL.
Empiric evidence of publication bias affecting acute stroke clinical trials
Stroke 1999;30:268
HSL7467
Direct-to-consumer pharmaceuticals: media trends, market leaders, market size, market growth and more
Magazine Publishers of America 1999
www.magazine.org
HSL7468
Magazines: a healthy diagnosis. Return on investment for DTC pharmaceutical advertising. A study measuring the effectiveness of allergy advertising by PERZ/HCI
Magazine Publishers of America 1999
www.magazine.org
HSL7471
Marley J.
Complaints: a personal view
Australian Prescriber 1999;22:80
http://www.australianprescriber.com/magazines/vol22no4/complaints.htm
HSL7475
Qizilbash N, Schneider L, Farlow M, Whitehead A, Higgins J.
Meta-analysis of tacrine for Alzheimer disease: the influence of industry sponsors
JAMA 1999;281:2287-2288
http://jama.ama-assn.org/issues/v281n24/ffull/jlt0623-7.html
HSL7476
Roberts I.
Competing interests still exist
BMJ 1999;318:465
http://www.bmj.com/cgi/content/full/318/7181/464/a#resp3
HSL7477
Rosen P.
Response to letter to the editor
Journal of Emergency Medicine 1999;17:905
HSL7478
Roughead EE.
The Australian Pharmaceutical Manufacturers Association Code of Conduct: guiding the promotion of prescription medicines
Australian Prescriber 1999;22:78-80
http://www.australianprescriber.com/magazines/vol22no4/conduct.htm
HSL7480
Sansgiry S, Sharp WT, Sansgiry SS.
Consumer understanding and interpretation of printed over-the-counter drug advertisements
Journal of Pharmaceutical Marketing & Management 1999;13(1):15-26
HSL7481
Shalansky S.
Conflicting opinions on conflict of interest
Canadian Journal of Hospital Pharmacy 1999;52:67-68
HSL7482
Smith D
The ties that bind? Weighing the risks and benefits of pharmaceutical industry sponsorship
Amsterdam: Health Action Interaction; 1999
www.haiweb.org
HSL7512
Haynes RB.
Drug dependence in a journal club: Editor's response
ACP Journal Club 1999;131(3):A13
http://www.acpjc.org/Content/131/3/ISSUE/ACPJC-1999-131-3-A13.htm
HSL8476
Jones M, Greenfield S, Bradley C.
Survey of the advertising of nine new drugs in the general practice literature
Journal of Clinical Pharmacy and Therapeutics 1999;24(6):451-460
www.blackwell-synergy.com/rd.asp?code=JCP&vol=24&page=451&goto=abstract
HSL8567
O'Connell CA, Skinner R.
Patient labeling program at Bristol-Myers Squibb
Drug Information Journal 1999;33(3):649-654
HSL8600
U.S. pharmaceutical industry spent more than $5.8 billion on product promotion in 1998: direct-to-consumer advertising expenditures exceed $1.3 billion
Massachusetts Pharmacy Journal 1999;11(1):12
HSL8608
Danjoh K.
Thinking globally: product development, registration, and marketing in the new millennium
Drug Information Journal 1999;33(1):327-332
HSL9701
Irwig J, Irwig L, Sweet M.
Smart Health Choices: How to make informed health decisions
Sydney: Allen & Unwin; 1999
Link to source with long URL
HSL10930
Harada K, Yamazaki S, Arakawa M, Fujimura A.
Survey of the attitudes of pharmacists and medical reprsentative toward drug interactions in daily practice
Japanese Journal of Clinical Pharmacology and Therapeutics 1999;30(6):783-791
HSL513
Jefferson BK.
Cal Ripken, Jr and Prinivil
;339(27):2024-5. N Engl J Med 1998 Dec 31;339(27):2024
Link to source with long URL
HSL5927
Wood AJ, Stein CM, Woosley R.
Making medicines safer--the need for an independent drug safety board.
N Engl J Med 1998 Dec 17;339(25):1851-4
http://content.nejm.org/cgi/content/extract/339/25/1851
HSL8775
Blecher MB, Haugh R, Hudson T, Serb C.
The year that was--what it means for 1999.
Hosp Health Netw 1998 Dec 5-20;72(23-24):26-8,
HSL8604
Smith D.
Is your message lost among the rose petals?
Pharmaceutical Executive 1998 Dec;18:18-19
HSL8605
Realto V.
Best of the best-1998 top 10
Pharmaceutical Executive 1998 Dec;18:6-11
HSL8815
Mangino MH, Szajna JL, Ptachcinski R, Skledar SJ.
Role of a pharmacy technician in implementing a prescription assistance program for indigent and underinsured patients
ASHP Midyear Clinical Meeting 1998 Dec;33
HSL550
Collier J.
Patient-information leaflets and prescriber competence.
Lancet 1998 Nov 28;352(9142):1724
Link to source with long URL
HSL8798
Hui KK.
Adverse drug reactions in hospitalized patients.
JAMA 1998 Nov 25;280(20):1742-3
HSL2354
Langreth R.
Drug Marketing Drives Many Clinical Trials
The Wall Street Journal 1998 Nov 16
HSL7430
O’hara J.
Whistle-blower: a top researcher says a drug under trial poses a risk to patients
Maclean’s 1998 Nov 16
HSL8731
Fleming H.
Front-end success
Drug Topics 1998 Nov 16;142:59-60, 62, 65, 67-68
HSL8807
Consumer ads build awareness but not understanding of advertised medications, surveys reveal
American Journal of Health System Pharmacy 1998 Nov 15;55:2344, 2347
HSL4159
Scott L.
Patient visits up for DTC conditions.
Newtown, Pa. 1998 Nov 6
http://www.scottlevin.com
HSL5516
McGhan WF.
Employer and consumer perspectives.
Value Health 1998 Nov 01;1(4):237-42
http://www.blackwell-synergy.com/doi/abs/10.1046/j.1524-4733.1998.140237.x
HSL536
Lal A.
Information contents of drug advertisements: an Indian experience.
Ann Pharmacother 1998 Nov;32(11):1234-8
http://www.theannals.com/cgi/reprint/32/11/1234
HSL532
Lexchin J.
Drug not considered a first-line agent.
Can Fam Physician 1998 Nov;44:2376
Nil
HSL7427
ACE inhibitors
Health Skepticism 1998 Nov;1(1):3-4
HSL7428
Law J.
Assessing the impact of direct-to-consumer advertising
Scrip Magazine 1998 Nov(73):21-22
HSL7429
Lexchin J.
Re: the promotion of Longifene (buclizine)
1998 Nov
HSL8747
Wechsler J.
Managed care and pharmaceutical costs
Pharmaceutical Executive 1998 Nov;18:18, 20-22
HSL8748
Meinhardt RA.
Congress takes aim at retail pharmacy pricing
Drug Benefit Trends 1998 Nov;10:21-22
HSL8773
Wechsler J.
Costs, coverage, and commercials
Pharmaceutical Technology 1998 Nov;22:14, 16, 18, 20, 22-24
HSL522
Pieters T.
Marketing medicines through randomised controlled trials: the case of interferon.
BMJ 1998 Oct 31;317(7167):1231-3
http://bmj.bmjjournals.com/cgi/content/full/317/7167/1231
HSL8801
Sykes R.
Being a modern pharmaceutical company: involves making information available on clinical trial programmes.
BMJ 1998 Oct 31;317(7167):1172
http://www.bmj.com/cgi/content/full/317/7167/1172
HSL5854
Bates DW, Leape LL, Cullen DJ, Laird N, Petersen LA, Teich JM, Burdick E, Hickey M, Kleefield S, Shea B, Vander Vliet M, Seger DL.
Effect of computerized physician order entry and a team intervention on prevention of serious medication errors.
JAMA 1998 Oct 21;280(15):1311-6
http://jama.ama-assn.org/cgi/content/full/280/15/1311
HSL512
Shuchman M.
Legal issues surrounding privately funded research cause furore in Toronto.
CMAJ 1998 Oct 20;159(8):983-6
http://www.cmaj.ca/cgi/reprint/159/8/983
HSL523
Phillips RA, Hoey J.
Constraints of interest: lessons at the Hospital for Sick Children.
CMAJ 1998 Oct 20;159(8):955-7
http://www.cmaj.ca/cgi/reprint/159/8/955
HSL7426
Drug advertising
Shown on: Canadian Broadcasting Corporation program Undercurrents 1998 Oct 18
HSL504
A meeting too many.
Lancet 1998 Oct 10;352(9135):1161
http://linkinghub.elsevier.com/retrieve/pii/S0140673698000324
HSL7418
Bero LA.
Corporate gifts to academic researchers [2nd of 2 replies]
JAMA 1998 Oct 9;280(10):884
HSL7419
Campbell EG, Blumental D, Louis KS.
Corporate gifts to academic researchers [1st of 2 replies]
JAMA 1998 Oct 9;280(10):884
HSL557
Azimi NA, Welch HG.
The effectiveness of cost-effectiveness analysis in containing costs.
J Gen Intern Med 1998 Oct;13(10):664-9
http://www.blackwell-synergy.com/doi/abs/10.1046/j.1525-1497.1998.00201.x
HSL5278
Phatak A.
The pharmaceutical industry and the medical profession.
Issues Med Ethics 1998 Oct-Dec;6(4):131-2
HSL7381
Gabb G.
Striking a balance in drug information--the Australian Medicines Handbook.
Aust N Z J Med 1998 Oct;28(5):675
HSL7393
Shapiro JD, Phillips KA, Tannock IF.
More pharmaceutical company influence?
Aust N Z J Med 1998 Oct;28(5):675
HSL7417
Aslam N.
Pharmaceuticals lack seriousness to provide more information on request
The Network’s Drug Bulletin 1998 Oct-Dec;7(5-6):12-16, 19
HSL7423
The drug pushers
Health Which? 1998 Oct
HSL7424
Lexchin J.
Re: the promotion of Claribid (clarithromycin)
1998 Oct
HSL7425
Rane W.
How ethical is the pharmaceutical industry in India
Rational Drug Bulletin 1998 Oct;8(4):4-5
HSL8753
Morais RJ.
Mastering the basics-10 steps to DTC
Pharmaceutical Executive 1998 Oct;18:63-65
HSL8754
Wechsler J.
Consumer advocates & pharmacists attack DTC ads
Pharmaceutical Executive 1998 Oct;18:8, 7
HSL8771
Waltermire RD.
Direct-to-consumer advertising of Rx drugs can be harmful to your health
Drug Benefit Trends 1998 Oct;10:60-61
HSL8787
Ohliger PC.
Discount or illegal payment?
Drug Benefit Trends 1998 Oct;10:27, 31
HSL8806
Murray MD, Deardorff FW.
Does managed care fuel pharmaceutical industry growth?
Pharmacoeconomics 1998 Oct;14(4):341-8
HSL7422
Public Citizen’s Health Research Group
Comments on: Food and Drug Administration: attitudinal and behavioral effects of direct-to-consumer advertising of prescription drugs
: Public Citizen’s Health Research Group; 1998 Sep 28
www.citizen.org
HSL8770
Vecchione A.
All in one
Drug Topics 1998 Sep 21;142:48
HSL8757
Fleming DJ, Samuels KW.
Direct-to-consumer advertising and the learned intermediary.
Hosp Pract (Minneap) 1998 Sep 15;33(9):129-30
HSL7420
Hsu J.
Corporate gifts to academic researchers.
JAMA 1998 Sep 9;280(10):883
http://jama.ama-assn.org/cgi/content/full/280/10/883
HSL7421
Trevett KP.
Corporate gifts to academic researchers.
JAMA 1998 Sep 9;280(10):883-4
HSL8805
Carbon C, Bax RP.
Regulating the use of antibiotics in the community.
BMJ 1998 Sep 5;317(7159):663-5
http://www.bmj.com/cgi/content/full/317/7159/663
HSL540
Kamat VR, Nichter M.
Pharmacies, self-medication and pharmaceutical marketing in Bombay, India.
Soc Sci Med 1998 Sep;47(6):779-94
Link to source with long URL
HSL7416
Abbott’s promotion of Claribid (clarithromycin): an example of the use of gifts
MaLAM International News 1998 Sep-Oct;16(9-10):1-2
HSL8766
Hewitt A, Jaquiss I.
Particle equation: company viewpoints
Pharmaceutical Executive 1998 Sep;18:128-130, 132, 134, 136, 138
HSL8767
Petersen C.
I read it over breakfast: print proves its appeal with some all-ink DTC campaigns
Pharmaceutical Executive 1998 Sep;18:6-8, 10, 12
HSL8768
Madell R.
High energy collision: where medical & consumer marketing intersect
Pharmaceutical Executive 1998 Sep;18:75-112
HSL8769
Smith D.
Can DTC programs improve patient compliance?
Pharmaceutical Executive 1998 Sep;18:14, 17
HSL8811
Wechsler J.
Safety first
Pharmaceutical Technology 1998 Sep;22:16, 18, 20, 22, 24, 26, 28
HSL511
Silversides A.
Private sector becoming the key to research funding in Canada.
CMAJ 1998 Aug 25;159(4):397-8
http://www.cmaj.ca/cgi/reprint/159/4/397
HSL534
Lexchin J.
Intellectual property rights and drug prices.
Lancet 1998 Aug 15;352(9127):582
Link to source with long URL
HSL7415
Go on, it’s good for you
The Economist 1998 Aug 8:51-52
HSL509
Smith R.
Beyond conflict of interest: Transparency is the key.
BMJ. 1998 Aug 1;317(7154):291-2
http://bmj.bmjjournals.com/cgi/content/full/317/7154/291
HSL7413
Consumer and physician attitudes toward direct-to-consumer advertising
: Time Inc.; 1998 Aug
HSL8759
Market share plans: NCPA analysis
America's Pharmacist 1998 Aug;120:25-27
HSL537
Krimsky S, Rothenberg LS.
Financial interest and its disclosure in scientific publications.
JAMA 1998 Jul 15;280(3):225-6
http://jama.ama-assn.org/cgi/content/full/280/3/225
HSL2462
Frances A, Kahn D, Carpenter D, Frances C, Docherty J.
A new method of developing expert consensus practice guidelines.
Am J Manag Care 1998 Jul;4(7):1023-9
http://www.ajmc.com/Article.cfm?Menu=1&ID=1662
HSL531
Lexchin J.
Residents and pharmaceutical representatives.
Can Fam Physician 1998 Jul;44:1448
Nil
HSL7410
Mintzes B
Paper tiger or toothless tabby? Regulation of prescription drug promotion in Canada
Vancouver: Health Policy Research Unit; 1998 Jul
HSL7411
MaLAM letter follow up—MaLAM apologises but we remain concerned about thepromotion of Atarax
MaLAM International News 1998 Jul-Aug;16(7-8):1-5
HSL7412
Sheldon T.
Drug promotion—how ethical is direct-to-consumer advertising?
Scrip Magazine 1998 Jul-Aug(70):21-22
www.pjbpubs.co.uk/scrip/scrhome.html
HSL7414
Milne C.
Let’s handle drug advertising carefully
Healthcare Manager 1998 Jul-Aug;3(5):5
HSL8762
Weiss S.
Generic drug industry: 1998 update
HealthCare Distributors 1998 Jul;50:38-40, 42, 44
HSL10753
Brewer D.
The effect of drug sampling policies on residents' prescribing.
Fam Med 1998 Jul-Aug;30(7):482-6
Link to source with long URL
HSL7409
Gilbert D
Direct-to-consumer advertising of prescription medicines
Surrey, United Kingdom: PJB Publications Ltd.; 1998 Jun 29
HSL521
Po AL, Zhang WY.
What lessons can be learnt from withdrawal of mibefradil from the market?
Lancet 1998 Jun 20;351(9119):1829-30
Link to source with long URL
HSL8816
Denman J.
Merck-sponsored simvastatin (Zocor) compliance program for patients using Wal-Mart pharmacy: of benefit to whom?: 3
Journal of the American Medical Association 1998 Jun 17;279:1876
HSL8817
Sherwood LM.
Merck-sponsored simvastatin (Zocor) compliance program for patients using Wal-Mart pharmacy: of benefit to whom?: 2
Journal of the American Medical Association 1998 Jun 17;279:1876
HSL8818
Hirsch RL.
Merck-sponsored simvastatin (Zocor) compliance program for patients using Wal-Mart Pharmacy: of benefit to whom?
JAMA 1998 Jun 17;279(23):1875-6
http://jama.ama-assn.org/cgi/content/full/279/23/1875-a
HSL8829
Hotchkiss BD, Pearson C, Lisitano R.
Pharmacy coordination of an indigent care program in a psychiatric facility.
Am J Health Syst Pharm 1998 Jun 15;55(12):1293-6
http://www.ajhp.org/cgi/reprint/55/12/1293
HSL545
Grossman L.
Ghostwriting.
Lancet 1998 Jun 6;351(9117):1741
Link to source with long URL
HSL506
Strandgaard S.
Conflict of interest in the debate over calcium-channel antagonists.
N Engl J Med 1998 Jun 4;338(23):1697-8
http://content.nejm.org/cgi/content/extract/338/23/1696
HSL528
Meltzer JI.
Conflict of interest in the debate over calcium-channel antagonists.
N Engl J Med 1998 Jun 4;338(23)
http://content.nejm.org/cgi/content/extract/338/23/1696
HSL525
Opie L.
Conflict of interest in the debate over calcium-channel antagonists.
N Engl J Med 1998 Jun 4;338(23):1696-7
http://content.nejm.org/cgi/content/extract/338/23/1696
HSL7407
Westfall J, McCabe J, Nicholas RA.
Drug samples: Benefit or bait? [reply]
JAMA 1998 Jun 3;276(21):1699
HSL7408
Wolf BL.
Drug samples: benefit or bait?
JAMA 1998 Jun 3;279(21):1698-9
http://jama.ama-assn.org/cgi/content/full/279/21/1698
HSL517
Roughead EE, Harvey KJ, Gilbert AL.
Commercial detailing techniques used by pharmaceutical representatives to influence prescribing.
Aust N Z J Med 1998 Jun;28(3):306-10
Nil
HSL549
Day R.
Pharmaceutical company promotion: striking a balance.
Aust N Z J Med 1998 Jun;28(3):291-3
Nil
HSL7405
Kendrick M.
The growing CME movement in Europe
Scrip Magazine 1998 Jun(69):45-47
www.pjbpubs.co.uk/scrip/scrhome.htm
HSL8765
Reissman D.
New drugs and DTC advertising: friend or foe?
Drug Benefit Trends 1998 Jun;10:16
HSL8785
McCarthy R.
Direct-to-consumer ads and cosmetic pharmacology
Drug Benefit Trends 1998 Jun;10:18
HSL8861
Grauer DW.
Impact of integrated systems on pharmaceutical purchasing: are rules and regulations keeping pace?
ASHP Annual Meeting 1998 Jun;55
HSL535
Levin AA.
Advertising prescription-only drugs.
Lancet 1998 May 23;351(9115):1583
Nil
HSL529
Medawar C.
Advertising prescription-only drugs.
Lancet 1998 May 23;351(9115):1584
Link to source with long URL
HSL526
Nightingale SL.
Advertising prescription-only drugs.
Lancet 1998 May 23;351(9115):1582
http://linkinghub.elsevier.com/retrieve/pii/S0140673698260211
HSL543
Inlander CB.
Advertising prescription-only drugs.
Lancet 1998 May 23;351(9115):1583
Link to source with long URL
HSL546
Goldstein MR.
Advertising prescription-only drugs.
Lancet 1998 May 23;351(9115):1583-4
Link to source with long URL
HSL553
Brown P.
Advertising prescription-only drugs.
Lancet 1998 May 23;351(9115):1582-3
http://linkinghub.elsevier.com/retrieve/pii/S0140673698260211
HSL538
Kelcher S, Brownoff R, Meadows LM.
Structured approach to pharmaceutical representatives. Family medicine residency program
Can Fam Physician 1998 May;44:1053-60
Nil
HSL4222
Tremayne WH.
Dollars & sense of the health care industry.
N J Med 1998 May 01;95(5):71-3
HSL8831
New products spurred 11% growth in pharmaceutical sales in 1997
American Journal of Health System Pharmacy 1998 May 1;55:880
HSL8833
Talley CR.
Confidentiality of patient records.
Am J Health Syst Pharm 1998 May 1;55(9):895
http://www.ajhp.org/cgi/reprint/55/9/895
HSL516
Schommer JC, Doucette WR, Mehta BH.
Rote learning after exposure to a direct-to-consumer television advertisement for a prescription drug.
Clin Ther 1998 May-Jun;20(3):617-32
Link to source with long URL
HSL7403
Drug Action Programme
WHO ethical criteria for medicinal drug promotion: a strategy for review and assessment of effectiveness
Geneva: World Health Organization; 1998 May
HSL7404
Lexchin J.
Re: the promotion of Duromine (phentermine)
1998 May
HSL8756
Smallcombe P.
Case study on the deregulation of Zovirax
Irish Pharmacy Journal 1998 May;76:136-137
HSL8758
Trend of the month: managed care, new products, and DTC efforts spur Rx sales growth
Drug Benefit Trends 1998 May;10:10-11
HSL8812
Lyftingsmo S.
Make the drug package for the patient-not for the doctor!
International Pharmacy Journal 1998 May-Jul;12:79
HSL8813
Hensley S.
Defying the prescription: Forget forecasts--drug sales soar under managed care
Modern Healthcare 1998 Apr 13;28:42
HSL514
Sharp D.
A ghostly crew.
Lancet 1998 Apr 11;351(9109):1076
Nil
HSL8772
Ukens C.
Reaching new heights
Drug Topics 1998 Apr 6;142:23
HSL8780
Tarlach GM.
Domino effect
Drug Topics 1998 Apr 6;142:29
HSL551
Campbell EG, Louis KS, Blumenthal D.
Looking a gift horse in the mouth: corporate gifts supporting life sciences research.
JAMA 1998 Apr 1;279(13):995-9
http://jama.ama-assn.org/cgi/content/full/279/13/995
HSL555
Bero LA.
Disclosure policies for gifts from industry to academic faculty.
JAMA 1998 Apr 1;279(13):1031-2
http://jama.ama-assn.org/cgi/content/full/279/13/1031
HSL5918
Schiff GD, Rucker TD.
Computerized prescribing: building the electronic infrastructure for better medication usage.
JAMA 1998 Apr 1;279(13):1024-9
http://jama.ama-assn.org/cgi/content/full/279/13/1024
HSL7402
Hunt M
Direct-to-consumer advertising of prescription drugs
Washington, D.C.: National Health Policy Forum, George Washington University; 1998 Apr
www.nhpf.org/ibonline.cfm#8-719
HSL503
Pushing ethical pharmaceuticals direct to the public.
Lancet 1998 3 28;351(9107):921
Nil
HSL8821
Gebhart F.
Annual Rx survey: new golden age
Drug Topics 1998 Mar 16;142:71-72, 74, 76, 83
HSL558
Hoen E.
Direct-to-consumer advertising: for better profits or for better health?
Am J Health Syst Pharm 1998 Mar 15;55(6):594-7
http://www.ajhp.org/cgi/reprint/55/6/594.pdf
HSL8859
't Hoen E
Direct to consumer advertising: for better profits or for better health?
American Journal of Health System Pharmacy 1998 Mar 15;55:594-597
HSL527
Melzer D.
New drug treatment for Alzheimer's disease: lessons for healthcare policy.
BMJ 1998 Mar 7;316(7133):762-4
http://bmj.bmjjournals.com/cgi/content/full/316/7133/762
HSL508
So AD.
Free gifts: redundancy or conundrum?
J Gen Intern Med 1998 Mar;13(3):213-
http://www.blackwell-synergy.com/doi/full/10.1046/j.1525-1497.1998.00058.x
HSL547
Gibbons RV, Landry FJ, Blouch DL, Jones DL, Williams FK, Lucey CR, Kroenke K.
A comparison of physicians' and patients' attitudes toward pharmaceutical industry gifts.
J Gen Intern Med 1998 Mar;13(3):151-4
http://www.blackwell-synergy.com/doi/abs/10.1046/j.1525-1497.1998.00048.x
HSL7399
PMAC continuing health education working group at ACME Canadian day
PMAC Update 1998 Mar:4-5
HSL7400
Lexchin J.
Re: the promotion of Atarax (hydroxyzine dichlorhydrate)
1998 Mar
HSL7401
3M claims Duromine (phentermine) has “Proven efficacy in general practice” and “A safety profile you have come to trust” but the evidence is thin
MaLAM International News 1998 Mar-Apr;16(3-4):1-2
HSL8764
Gander P
What next for patient packaging?
Manufacturing Chemist 1998 Mar;69:18-19
HSL8810
Yaguda S.
Take to the air by radio
Pharmaceutical Executive 1998 Mar;18:72, 74, 76
HSL8858
Simmonds H.
Prescription medicines Code of Practice Authority investigates criticisms of advertisements.
BMJ 1998 Feb 7;316(7129):476
HSL8804
Meyer H.
The pills that ate your profits.
Hosp Health Netw 1998 Feb 5;72(3):18-22
HSL544
Huston P, Campbell NR.
Influencing prescribing patterns.
Can Fam Physician 1998 Feb;44:221-3,
Nil
HSL7397
American Academy of Neurology policy on conflicts of interest: Ethics and Humanities Subcommittee.
Neurology. 1998 Feb;50(2):332-4
HSL7398
Bernat JL, Goldstein ML, Ringel SP.
Conflicts of interest in neurology.
Neurology 1998 Feb;50(2):327-31
HSL8826
Reid S.
New ways to take medicine
Pharmaceutical Executive 1998 Feb;18:70-72, 74
HSL14018
Jacoby J, Johar GV, Morrin M.
Consumer Behavior: A Quadrennium
Annual Review of Psychology 1998 Feb;49:319-344
http://www.ovid.com/site/catalog/Journal/273.jsp
HSL2443
McColl A, Smith H, White P, Field J.
General practitioner's perceptions of the route to evidence based medicine: a questionnaire survey.
BMJ 1998 Jan 31;316(7128):361-5
http://bmj.bmjjournals.com/cgi/content/full/316/7128/361
HSL542
Ioannidis JP.
Effect of the statistical significance of results on the time to completion and publication of randomized efficacy trials.
JAMA 1998 Jan 28;279(4):281-6
http://jama.ama-assn.org/cgi/content/full/279/4/281
HSL5872
Evans RS, Pestotnik SL, Classen DC, Clemmer TP, Weaver LK, Orme JF Jr, Lloyd JF, Burke JP.
A computer-assisted management program for antibiotics and other antiinfective agents.
N Engl J Med 1998 Jan 22;338(4):232-8
http://content.nejm.org/cgi/content/abstract/338/4/232
HSL505
Sukkari SR, Sasich LD.
Trials of CCBs.
CMAJ 1998 Jan 13;158(1):21-3
http://www.cmaj.ca/cgi/reprint/158/1/21
HSL548
Stelfox HT, Chua G, O'Rourke K, Detsky AS.
Conflict of interest in the debate over calcium-channel antagonists.
N Engl J Med 1998 Jan 8;338(2):101-6
http://content.nejm.org/cgi/content/abstract/338/2/101
HSL7396
Increased US drug consumption driven by increased spending on direct to the consumer promotion
MaLAM International News 1998 Jan-Feb;16(1-2):2
HSL8799
Heller A.
New technology advances pharmacy productivity
Drug Store News Chain Pharm 1998 Jan;8
HSL8800
Frederick J.
Search continues for next generation of drugs
Drug Store News Chain Pharm 1998 Jan;8
HSL8819
McCarthy R.
Rx ads hit consumer bull's eye
Drug Benefit Trends 1998 Jan;10:23
HSL8836
Craig RP.
Patient as a partner in prescribing: direct to consumer advertising
Journal-of-Managed-Care-Pharmacy 1998 Jan-Feb;4:15-16, 18-19
HSL8865
Nordenberg T.
Direct to you: TV drug ads that make sense.
FDA Consum 1998 Jan-Feb;32(1):7-10
HSL520
Reeves KN.
Direct-to-consumer broadcast advertising: empowering the consumer or manipulating a vulnerable population?
Food Drug Law J 1998;53(4):661-79
Nil
HSL519
Roughead EE, Gilbert AL, Harvey KJ.
Self-regulatory codes of conduct: are they effective in controlling pharmaceutical representatives' presentations to general medical practitioners?
Int J Health Serv 1998;28(2):269-79
Nil
HSL502
Wagner E.
Ghostwriting
The Lancet 1998;351:1741
Nil
HSL533
Lexchin J.
Improving the appropriateness of physician prescribing.
Int J Health Serv 1998;28(2):253-67
Nil
HSL524
Parker BJ, Delene LM.
Direct-to-consumer prescription drug advertising: content analyis and public policy implications
Journal of Pharmaceutical Marketing & Management 1998;12(4):27
Nil
HSL2221
Creyer EH, Hrsistodoulakis I.
Marketing pharmaceutical products to physicians. Sales reps influence physicians' impressions of the industry
Mark Health Serv. 1998 Sum;18(2):34-8
HSL2356
Bourguignon R.
Problems with Prozac
1998
HSL2718
Powers R
Time with drug reps affects prescribing.
1998
Nil
HSL4167
Brown P.
Will DTC advertising shape the future of the industry?
Scrip Mag. 1998:3-4
HSL5856
Beck JM, Azari ED.
FDA, off-label use, and informed consent: debunking myths and misconceptions.
Food Drug Law J 1998;53(1):71-104
HSL5911
Pizor , TC .
A medical publisher reminds us: don't forget the gatekeepers
Med Mark Media 1998;33:65-67
HSL6906
O-Brien KL.
Epidemic of pediatric deaths from acute renal failure caused by diethylene glycol poisoning
JAMA 1998;279:1180
HSL7371
Medicating for a mirage
International Journal of Risk & Safety in Medicine 1998;11:1-3
HSL7372
National survey of consumer reactions to direct-to-consumer advertising
Pennsylvania: Rodale Press; 1998
HSL7373
Spotlight: BMS vs CCOHTA
Connection 1998
www.ccohta.ca
HSL7374
Ault A.
US FDA ordered to allow off-label data dissemination
Lancet 1998;352:555
HSL7375
Bauer G.
Pitching drugs to patients
Pharmacy Practice 1998;14(12):43-44, 46, 48
www.pharmacyconnects.com/pharPrac/index.htm
HSL7376
Baylor-Henry M, Drezin NA.
Regulation of prescription drug promotion: direct-to-consumer advertising.
Clin Ther 1998;20
HSL7377
Brock TP, Smith MC.
A content analysis of the appeals used in advertising in the Americal Journal of Hospital Pharmacy in 1960, 1970, 1980, and 1990
Journal of Pharmaceutical Marketing & Management 1998;12(4):43
HSL7378
Center for Drug Evaluation and Research
CDER 1997: report to the nation
: U.S. Department of Health and Human Services; 1998
HSL7379
Day M.
He who pays the piper . . .
New Scientist 1998;158(2133):18-19
HSL7380
Fried S.
Bitter pills: inside the hazardous world of legal drugs
New York: Bantam Books; 1998
HSL7382
Gutkin C.
Pharmaceutical industry and the medical profession
Canadian Family Physician 1998;44:1756
HSL7383
Hoey J.
Placing the ads
Canadian Medical Association Journal 1998;159:920
http://www.cma.ca/cmaj/vol-159/issue-8/0920b.htm
HSL7384
Kassirer J.
Cal Ripken, Jr., and prinivil
New England Journal of Medicine 1998;339:2025
HSL7385
Lexchin J.
Placing the ads
Canadian Medical Association Journal 1998;159:920
http://www.cma.ca/cmaj/vol-159/issue-8/0920a.htm
HSL7386
Lexchin J.
The relationship between pharmaceutical regulation and inappropriate prescribing: the case of psychotropic drugs in Canada during the 1960s and early 1970s
International Journal of Risk & Safety in Medicine 1998;11:49-59
HSL7387
Lexchin J, North P.
OMA perspective on comparative advertising of pharmaceutical products
Ontario Medical Review 1998;65(5):25-27
HSL7389
Mintzes B
Blurring the boundaries: new trends in drug promotion
Amsterdam: Health Action International; 1998
www.haiweb.org
HSL7390
Morgan S
Issues for Canadian pharmaceutical policy: Striking a balance: health care systems in Canada and elsewhere
Sainte-Foy, Canada: Sainte-Foy, Canada; 1998
HSL7391
Powers RL, Halbritter KA, Arbogast JG, Neely JL, Williams AJ.
Do interactions with pharmaceutical representatives influence antihypertensive medication prescribing practices of family medicine and general internal medicine physicians?
Journal of General Internal Medicine 1998;13:13
HSL7392
Shannon TM.
Trials of CCBs
Canadian Medical Association Journal 1998;158:21-23
http://www.cma.ca/cmaj/vol-158/issue-1/0021b.htm
HSL7394
Sherwood LM.
Cal Ripken, Jr., and prinivil
New England Journal of Medicine 1998;339:2025
HSL7395
Valpy M.
Science friction
Elm Street 1998:26-28, 30, 32, 34-36
HSL7406
McCormack J.
Drug ad hard to swallow
Adbusters 1998:18-19
www.adbusters.org/adbusters/
HSL8728
Pines WL.
Direct-to-consumer promotion: an industry perspective.
Clin Ther 1998;20
HSL8729
Maine LL.
Direct-to-consumer advertising: a pharmacy perspective.
Clin Ther 1998;20
HSL8752
Doucette WR, Schommer JC.
Consumer preferences for drug information after direct-to-consumer advertising
Drug Information Journal 1998;34(4):1081-1088
HSL8792
McCaffrey DJ, Smith MC, Banahan BF, Frate DA, Gilbert FW.
Continued look into the financial implications of initial noncompliance in community pharmacies: unclaimed prescription audit pilot
Journal of Research in Pharmaceutical Economics 1998;9(2):33-57
HSL8794
Wechsler J.
Message to marketers: take the high road
Pharmaceutical Executive 1998;1(2):28-29
HSL8796
Smith D.
It's our health...and we want more than advertising
Pharmaceutical Executive 1998;1(2):23-24
HSL8797
DTC data
Pharmaceutical Executive 1998;1(2):33-34
HSL8809
Lasagna L.
Defining our future work.
Pharmacoeconomics 1998;14
HSL9735
Moynihan R.
Too much medicine? The Business of Health - and Its Risks for You
Sydney: ABC Books; 1998
Link to source with long URL
HSL12241
Miller D.
Mediating Science: promotional strategies, media coverage, public belief and decision making
Scanlon E, Whitelegg E, Yates S. Communicating Science: Contexts and Channels London: Routledge/Open University; 1998
Link to source with long URL
HSL14021
Keller KL.
Strategic Brand Management: Building, Measuring, and Managing Brand Equity
New Jersey: Prentice Hall; 1998
Link to source with long URL
HSL14109
Lapeyre-Mestre M, Desboeuf K, Aptel I, Chale JJ, Montastruc JL.
A comparative survey of antidepressant drug prescribing habits of general practitioners and psychiatrists.
Clin Drug Investig 1998;16(1):53-61
http://www.ncbi.nlm.nih.gov/pubmed/18370518
HSL694
Menkes DB.
Hazardous drugs in developing countries.
BMJ 1997 Dec 13;315(7122):1557-8
http://bmj.bmjjournals.com/cgi/content/full/315/7122/1557
HSL708
Lewin-Fetter V.
Pharmaceutical representatives.
Lancet 1997 Dec 13;350(9093):1784
HSL1829
Mansfield PR.
MaLAM, a medical lobby for appropriate marketing of pharmaceuticals.
Med J Aust 1997 Dec 1-15;167(11-12):590-2
http://www.mja.com.au/public/issues/xmas/mansfield/mansfield.html
HSL8868
Americans at risk from self-medication, survey reveals
American Journal of Health System Pharmacy 1997 Dec 1;54:2664, 2666
HSL704
Lipsky MS, Taylor CA.
The opinions and experiences of family physicians regarding direct-to-consumer advertising.
J Fam Pract 1997 Dec;45(6):495-9
HSL7370
Mansfield P, Vitry A.
Re: the promotion of prescription products in Australia
1997 Dec
HSL8814
Tanouye E, Langreth R.
U.S. drug patents
Eastern Pharmacist 1997 Dec;40:21-24
HSL8820
Reissman D.
Who's taking the risk for prescription drug costs?
Drug Benefit Trends 1997 Dec;9:19
HSL8823
Wechsler J.
Direct-to-marketers: FDA talks to the industry
Pharmaceutical Executive 1997 Dec;17:52-54, 56, 58, 60, 62
HSL8862
Wechsler J.
Final reform bill modernizes FDA, permits dissemination of off-label and economic data
Formulary 1997 Dec;32:1253-1254
HSL8880
Hicks AR, Jackson MW, Barnard JF.
Pharmacoeconomic strategies for treating HIV patients in an indigent clinic
ASHP Midyear Clinical Meeting 1997 Dec;32
HSL8881
Habowski SR, Robinson SM, Kalis D.
Establishing an indigent prescription program in the ambulatory care setting
ASHP Midyear Clinical Meeting 1997 Dec;32
HSL13979
Aaker JL, Maheswaran D.
The Effect of Cultural Orientation on Persuasion
Journal of Consumer Research 1997 Dec;24(3):315-27
http://www.journals.uchicago.edu/doi/abs/10.1086/209513
HSL742
Alliot L.
Quality of drug advertisements in medical journals.
Lancet 1997 Nov 29;350(9091):1636
HSL7362
Chiu JT.
Personal use of drug samples by physicians and office staff.
JAMA 1997 Nov 19;278(19):1568
HSL7363
Limaye AP, Paauw DS.
Personal use of drug samples by physicians and office staff.
JAMA 1997 Nov 19;278(19):1568-9
HSL7364
Margolis LH.
Personal use of drug samples by physicians and office staff.
JAMA 1997 Nov 19;278(19):1567
HSL7365
Mehta HJ.
Personal use of drug samples by physicians and office staff.
JAMA 1997 Nov 19;278(19):1568
HSL7366
Reynolds S.
Personal use of drug samples by physicians and office staff.
JAMA 1997 Nov 19;278(19):1567-8
HSL7367
Rosner F.
Personal use of drug samples by physicians and office staff.
JAMA 1997 Nov 19;278(19):1567
HSL7368
Tenery RM Jr.
Personal use of drug samples by physicians and office staff.
JAMA 1997 Nov 19;278(19):1568
HSL7369
Westfall J, McCabe J, Nicholas RA.
Personal use of drug samples by physicians and office staff [reply]
JAMA 1997 Nov 19;278(19):1569
HSL560
Vitry A, Mansfield P.
Drug advertisements in medical journals.
Lancet 1997 Nov 15;350(9089):1477-8
Link to source with long URL
HSL724
Flegel KM.
Physicians, finder's fees and free, informed consent.
CMAJ 1997 Nov 15;157(10):1373-4
http://www.cma.ca/cmaj/vol-157/issue-10/1373.htm
HSL8870
Rothermich EA, Pathak DS.
References for health-related quality-of-life claims in prescription drug advertisements.
Am J Health Syst Pharm 1997 Nov 15;54(22):2596-9
http://www.ajhp.org/cgi/reprint/54/22/2596
HSL705
Lexchin J.
Code of marketing practices.Voluntary self-regulation for the Pharmaceutical Manufacturers Association of Canada
Can Fam Physician. 1997 11 01;43
HSL720
Guyatt G.
Determining an ethical stance: Pharmaceutical industry involvement and family medicine residency training
Can Fam Physician 1997 Nov 01;43:1898-900
HSL700
Mahood S, Zagozeski C, Bradel T, Lawrence K.
Pharmaceutical policies in Canadian family medicine training. Survey of residency programs
Can Fam Physician 1997 Nov;43:1947-51
Nil
HSL2185
Shaughnessy AF, Bucci KK.
Drug samples and family practice residents.
Ann Pharmacother 1997 Nov;31(11):1296-300
HSL7356
Christensen TP, Ascione FJ, Bagozzi RP.
Understanding how elderly patients process drug information: a test of a theory of information processing.
Pharm Res 1997 Nov;14(11):1589-96
http://www.springerlink.com/content/j710827lt8226251/
HSL7357
Lumley P.
Forging closer links with patients
Scrip Magazine 1997 Nov(62):19-20
www.pjbpubs.co.uk/scrip/scrhome.html
HSL7358
Prettejohn R.
Making the most of meetings
Scrip Magazine 1997 Nov(62):11-12
HSL7359
Sorell T.
Sponsors, ethics and the NHS
Scrip Magazine 1997 Nov(62):7-9
www.pjbpubs.co.uk/scrip/scrhome.html
HSL7360
Weinblatt L.
DTC advertisers—you’re wasting your money
Medical Marketing & Media 1997 Nov;32(11):47-51
HSL7361
Sweet M.
Healthy profits (part 3)
MaLAM International News 1997 Nov-Dec;15(11-12):1-4
HSL8825
Maximize your prescription drug investment
Managed Healthcare 1997 Nov;7:46-47
HSL8827
McCann B.
How will FDA reform affect the generic industry?
Drug Topics 1997 Nov;141
HSL8830
Akanmu O.
Nigeria-strategy and strength for industry
Pharmaceutical Executive 1997 Nov;17:74-78
HSL674
Sternberg EM.
Intimidation of researchers by special-interest groups.
N Engl J Med 1997 Oct 30;337(18):1316
Link to source with long URL
HSL722
Fardon DF, Garfin SR, Saal JA.
Intimidation of researchers by special-interest groups.
N Engl J Med 1997 Oct 30;337(18):1315-6
HSL3133
Katsanis , Prevel L, Olivanti , Christina C.
A review of patient education in promotional activities. Sponsored by the Canadian pharmaceutical industry: a descriptive study
1997 Oct 4
http://www.fadmin.unb.ca/asb/paper42.htm
HSL8871
Talley CR.
Direct-to-consumer prescription drug advertising.
Am J Health Syst Pharm 1997 Oct 1;54(19):2181
http://www.ajhp.org/cgi/reprint/54/19/2181
HSL682
Sandberg WS, Carlos R, Sandberg EH, Roizen MF.
The effect of educational gifts from pharmaceutical firms on medical students' recall of company names or products.
Acad Med 1997 Oct;72(10):916-8
Nil
HSL717
Hopper JA, Speece MW, Musial JL.
Effects of an educational intervention on residents' knowledge and attitudes toward interactions with pharmaceutical representatives.
J Gen Intern Med 1997 Oct;12(10):639-42
HSL8854
Schwartz H.
On the money
Pharmaceutical Executive 1997 Oct;17:26, 28, 30
HSL8855
Madell R.
DTC unleashed: review & reactions
Pharmaceutical Executive 1997 Oct;17:68-70, 72, 74
HSL8856
Wechsler J.
Marketing to Medicare & Kiddie Care
Pharmaceutical Executive 1997 Oct;17:20, 22, 24
HSL8857
Wood J, Rupright P.
Erosion of the learned intermediary rule
Pharmaceutical Executive 1997 Oct;17:104, 106, 108, 110
HSL8822
Sims J.
Who will be able to prescribe?
Pharmacy in Practice 1997 Oct;7:497, 500, 502
HSL8837
Kauffman-Sherr M, Cutrone-Hoffman D
Physicians-gatekeepers to DTC success
Pharmaceutical Executive 1997 Oct;17:56-58, 62, 64, 66
HSL8838
Gopal K.
Patients as partners
Pharmaceutical Executive 1997 Oct;17:32, 34
HSL8867
Wechsler J.
Washington report: Medicare, child care and TV advertising
Pharmaceutical Technology Europe 1997 Oct;9:20, 22, 24, 26
HSL709
Langer A.
Early stopping of trials.
Lancet 1997 Sep 20;350(9081):890-1
HSL718
Hopf G.
Early stopping of trials.
Lancet 1997 Sep 20;350(9081):891
HSL675
Stern JM, Simes RJ.
Publication bias: evidence of delayed publication in a cohort study of clinical research projects.
BMJ 1997 Sep 13;315(7109):640-5
http://bmj.bmjjournals.com/cgi/content/full/315/7109/640
HSL7354
Tramer MR, Reynolds DJ, Moore RA, McQuay HJ.
Impact of covert duplicate publication on meta-analysis: a case study.
BMJ 1997 Sep 13;315(7109):635-40
Link to source with long URL
HSL714
Hueston WJ, Mainous AG 3rd.
A comparison of the numbers of pharmaceutical advertising pages in family medicine research journals and journals in other medical disciplines.
Acad Med 1997 Sep;72(9):804-6
HSL2710
Kazmierczak R, Coley KC.
Impact of Dear Doctor letters on prescribing: evaluation of the use of tramadol HCl
Formulary 1997 Sep;32:968, 977-978
Nil
HSL7350
Knowledge is the best medicine program launched in Quebec
PMAC News 1997 Sep-Oct:10-11
HSL7351
PMAC Code of Marketing Practices: amendments emphasize quality in continuing health education programs
PMAC News 1997 Sep-Oct:9
HSL7352
Sweet M.
Health profits (part 2)
MaLAM International News 1997 Sep-Oct;15(9-10):1-4
HSL8751
Vaught DV.
Vaught's views
Illinois Pharmacist 1997 Sep-Oct;59:34-36
HSL723
Gitanjali B, Shashindran CH, Tripathi KD, Sethuraman KR.
Are drug advertisements in Indian edition of BMJ unethical?
BMJ 1997 Aug 23;315(7106):459
http://www.bmj.com/cgi/content/full/315/7106/459
HSL733
Christo GG, Balasubramaniam R.
Commentary: advertising adversities.
BMJ 1997 Aug 23;315(7106):460
http://www.bmj.com/cgi/content/full/315/7106/460
HSL7311
Greenhalgh T.
How to read a paper.
Papers that report drug trials 1997 Aug 23
http://www.bmj.com/cgi/content/full/315/7106/480
HSL4145
FDA proposes new guidance on direct-to-consumer ads.
Scrip. 1997 Aug 15;2258:12
HSL14046
Wilke M.
GLaxo Pumps $55 Mil Into Zyban DTC Push: Anti-depressant Will Be Touted As Aid To Quit Smoking Cigarettes
Advertising Age 1997 Aug 11
http://adage.com/abstract.php?article_id=71118
HSL7349
Pill pushers
The Economist 1997 Aug 9:56-57
HSL8869
Raynor DK, Yerassimou N.
Medicines information--leaving blind people behind?
BMJ 1997 Aug 2;315(7103):268
http://www.bmj.com/cgi/content/full/315/7103/268
HSL5889
Lupton D.
Consumerism, reflexivity and the medical encounter.
Soc Sci Med 1997 Aug 01;45(3):373-81
Link to source with long URL
HSL8875
Schwartz DN.
Management of Helicobacter pylori-positive patients with dyspepsia.
Ann Intern Med 1997 Aug 1;127(3):244
http://www.annals.org/cgi/content/full/127/3/244
HSL7348
Lexchin J, Vitry A.
Re: the promotion of Ambatrol (nifuroxazide)
1997 Aug
HSL7347
Vecchione A.
Direct concerns: Pharmacists wary of surge in consumer Rx drug ads
Drug Topics 1997 Jul 21;141(14):36,37
HSL2449
Hemminki E, McPherson K.
Impact of postmenopausal hormone therapy on cardiovascular events and cancer: pooled data from clinical trials.
BMJ 1997 Jul 19;315(7101):149-53
http://bmj.bmjjournals.com/cgi/content/full/315/7101/149
HSL561
Viberti G, Slama G, Pozza G, Czyzyk A, Bilous RW, Gries A, Keen H, Fuller JH, Menzinger G.
Early closure of European Pimagedine trial. Steering Committee. Safety Committee.
Lancet 1997 Jul 19;350(9072):214-5
http://linkinghub.elsevier.com/retrieve/pii/S0140673697260290
HSL563
A curious stopping rule from Hoechst Marion Roussel.
Lancet 1997 Jul 19;350(9072):155
http://linkinghub.elsevier.com/retrieve/pii/S0140673697210299
HSL8960
Thompson CA.
Drug information industry reacts to private-sector plan for useful content
American Journal of Health System Pharmacy 1997 Jul 15;54:1572, 1575
HSL678
Sharfstein J.
Pfizer Night at Boston Billiards.
N Engl J Med 1997 Jul 10;337(2):134
Link to source with long URL
HSL559
Westfall JM, McCabe J, Nicholas RA.
Personal use of drug samples by physicians and office staff.
JAMA 1997 Jul 9;278(2):141-3
Link to source with long URL
HSL739
Cho M.
Disclosing conflicts of interest.
Lancet 1997 Jul 5;350(9070):72-3
HSL7343
Promotional war for genital herpes drugs
MaLAM Australian News 1997 Jul-Aug;5(7-8):2-3
HSL7344
Brown P.
Talking to patients—a dangerous road for industry?
Scrip Magazine 1997 Jul-Aug(59):3-4
www.pjbpubs.co.uk/scrip/scrhome.html
HSL7345
Hayes L, Mintzes B.
The ties that bind: drug industry sponsorship
HAI-Lights 1997 Jul-Aug;2(2-3):1-5
HSL7346
Sweet M.
Healthy profits: an overview of promotion in Australia
MaLAM International News 1997 Jul-Aug;15(7-8):1-4
HSL8864
Briscoe AP, Pancerella MB, Pleskunas G.
Perfect order initiative
Pharmaceutical Executive 1997 Jul;17:82, 84, 86, 88
HSL8874
Navarro RP.
Dissecting drug cost trends.
Med Interface 1997 Jul;10(7):80-2
HSL2411
Shuchman M, Wilkes MS.
Medical scientists and health news reporting: a case of miscommunication.
Ann Intern Med 1997 Jun 15;126(12):976-82
http://www.annals.org/cgi/content/full/126/12/976
HSL732
Davidoff F.
Where's the bias?
Ann Intern Med 1997 Jun 15;126(12):986-8
http://www.acponline.org/journals/annals/15jun97/wherbias.htm
HSL8962
Consumers receive written information with most prescriptions, report indicates.
Am J Health Syst Pharm. 1997 Jun 15;54(12):1381, 1386, 1388
http://www.ajhp.org/cgi/reprint/54/12/1381
HSL562
[No authors listed]
Good manners for the pharmaceutical industry.
Lancet 1997 Jun 7;349(9066):1635
http://linkinghub.elsevier.com/retrieve/pii/S0140673697210238
HSL676
Smith R.
Conflict of interest in clinical research: opprobium or obsession?
Lancet 1997 Jun 7;349(9066):1703
Link to source with long URL
HSL680
Scheifele DW.
Clinical trials and tribulations: a personal view of interacting with pharmaceutical manufacturers.
Clin Invest Med 1997 Jun;20(3):188-92
Nil
HSL690
Palmlund I.
The marketing of estrogens for menopausal and postmenopausal women.
J Psychosom Obstet Gynaecol 1997 Jun;18(2):158-64
Nil
HSL695
McElwain M.
Recent progress in drug advertising.
Can Fam Physician 1997 Jun;43:1041-2
Nil
HSL701
Madhavan S, Amonkar MM, Elliott D, Burke K, Gore P.
The gift relationship between pharmaceutical companies and physicians: an exploratory survey of physicians.
J Clin Pharm Ther 1997 Jun;22(3):207-15
Nil
HSL726
Dukes MN.
The menopause and the pharmaceutical industry.
J Psychosom Obstet Gynaecol 1997 Jun;18(2):181-8
HSL2346
Becel B, Bardelay D
A french physician's network monitoring medical representatives
Prescrire 1997 Jun
HSL7341
Vitry A, Mansfield P.
Re: breaches of the APMA Code of Conduct
1997 Jun
HSL8824
Employer/employee relations committee
Carolina Journal of Pharmacy 1997 Jun-Aug;77:6-7
HSL8873
Cohen MR.
Call for an end to unsafe abbreviations in journal ads
Hospital Pharmacy 1997 Jun;32:835-836
HSL7338
Advertisements for donepezil (Aricept) in the BMJ [Editor's response]
BMJ 1997 May 24;314:1556
http://bmj.com/cgi/content/full/314/7093/1555
HSL7339
Gray S.
Advertisements for donepezil (Aricept) in the BMJ: Advertisement suggests an unrealistic improvement in mental status
BMJ 1997 May 24;314:1555
http://bmj.com/cgi/content/full/314/7093/1555
HSL7340
Wagner N.
Advertisements for donepezil (Aricept) in the BMJ: Local committee has declined to approve NHS hospital prescription of donepezil.
BMJ 1997 May 24;314(7093):1555-6
http://bmj.com/cgi/content/full/314/7093/1555
HSL716
Horton R.
Sponsorship, authorship, and a tale of two media.
Lancet 1997 May 17;349(9063):1411-2
HSL8965
Lisi DM.
Ethical issues for pharmacists in managed care.
Am J Health Syst Pharm 1997 May 1;54(9):1041-2,
http://www.ajhp.org/cgi/reprint/54/9/1041
HSL2218
Lexchin J.
What information do physicians receive from pharmaceutical representatives?
Can Fam Physician 1997 May;43:941-5
Nil
HSL7332
Beaufour-Ipsen’s promotion of Smecta (smectite)
MaLAM International News 1997 May-Jun;15(5-6):1-2
HSL7333
Health and medical reporting: PMAC sponsored medical journalism program
PMAC News 1997 May-Jun:6
HSL7334
MaLAM complaints to the APMA
MaLAM Australian News 1997 May-Jun;5(5-6):1
HSL7335
MaLAM letter follow up—Rhone Poulenc Rorer’s promotion of Flagyl (metronidazole)
MaLAM International News 1997 May-Jun;15(5-6):2
HSL7336
Program update
PMAC News 1997 May-Jun:8-9
HSL7337
Servier resists but MaLAM persists!
MaLAM Australian News 1997 May-Jun;5(5-6):2
HSL8882
Janssen tops list of '96 nursing home sales leaders; Glaxo first in total US sales, Novartis first in global sales
Consultant Pharmacist 1997 May;12:610
HSL686
Raveendran R, Gitanjali B.
Conflict of interest.
Lancet 1997 Apr 19;349(9059):1173-4
Link to source with long URL
HSL696
McCarthy M.
Sponsors lose fight to stop thyroxine study publication.
Lancet 1997 Apr 19;349(9059):1149